COMBIPRES Drug Patent Profile

Which patents cover Combipres, and what generic alternatives are available?

Combipres is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in COMBIPRES is chlorthalidone; clonidine hydrochloride. There are twenty-one drug master file entries for this compound. Additional details are available on the chlorthalidone; clonidine hydrochloride profile page.

Summary for COMBIPRES

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	71
DailyMed Link:	COMBIPRES at DailyMed

US Patents and Regulatory Information for COMBIPRES

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-003	Apr 10, 1984		DISCN	Yes	No

Expired US Patents for COMBIPRES

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-001	Approved Prior to Jan 1, 1982	3,454,701
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-003	Apr 10, 1984	3,454,701
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-002	Approved Prior to Jan 1, 1982	3,454,701

International Patents for COMBIPRES

See the table below for patents covering COMBIPRES around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	42564
Denmark	117000
Switzerland	437316	Verfahren zur Herstellung von substituierten Phenyl-amino-1,3-diazacyclopenten-(2)-Verbindungen
France	1448765	Procédé pour fabriquer des nouveaux phénylamino-1, 3-diazacyclopentènes-(2)-substitués

COMBIPRES Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Drug-Device Combination Products: A Focus on COMBIPRES

Introduction

Drug-device combination products, such as COMBIPRES, are revolutionizing the healthcare industry by offering innovative solutions that combine the benefits of pharmaceuticals and medical devices. This article delves into the market dynamics and financial trajectory of these products, with a specific focus on COMBIPRES, a combination product used for hypertension.

Market Growth and Drivers

The global market for drug-device combination products is experiencing significant growth, driven by several key factors.

Technological Advancements

Technological advancements are a major driver, enabling the development of more sophisticated and effective combination products. For instance, the integration of digital health technologies and smart drug delivery systems is enhancing patient compliance and treatment outcomes[1].

Regulatory Environment

Favorable regulatory environments are also contributing to the growth. Regulatory bodies are increasingly supportive of innovative products that improve patient care, which encourages more investments in research and development[1].

Chronic Diseases and Aging Population

The rising prevalence of chronic diseases and an aging population are driving the demand for minimally invasive treatments. Products like COMBIPRES, which combine a drug (clonidine and chlorthalidone) with a delivery system, are particularly appealing as they offer better patient compliance and outcomes[1].

Regional Analysis

The market for drug-device combination products varies significantly across different regions.

United States

The U.S. market was estimated at $30.6 billion in 2023 and is expected to continue growing. Products like COMBIPRES, which are used to manage hypertension, are in high demand due to the prevalence of cardiovascular diseases in the U.S. population[1].

China

China is forecasted to grow at an impressive 8.3% CAGR, reaching $36.2 billion by 2030. This growth is driven by increasing healthcare spending and a growing middle class with greater access to advanced medical treatments[1].

Other Key Regions

Other regions, including Japan, Canada, Germany, and the Asia-Pacific, are also showing promising growth trends. These markets are driven by similar factors such as technological advancements, regulatory support, and the need for effective treatments for chronic diseases[1].

Financial Trajectory

The financial performance of companies involved in drug-device combination products is robust and promising.

Revenue Projections

The global market for drug-device combination products is projected to reach $158.7 billion by 2030, growing at a CAGR of 4.7% from 2023 to 2030. This growth is underpinned by strong revenue performances from segments such as transdermal patches and inhalers[1].

Example: UCB's Financial Performance

Companies like UCB are experiencing significant growth driven by their innovative products. For example, UCB's revenue in 2023 reached €5.25 billion, with strong growth from newly launched products like EVENITY, FINTEPLA, and BIMZELX. This growth is expected to continue, with UCB forecasting a growing top line and stable adjusted EBITDA margin for 2024[2].

Product-Specific Analysis: COMBIPRES

COMBIPRES, a combination of clonidine and chlorthalidone, is used to treat hypertension.

Market Position

COMBIPRES benefits from being part of a growing market segment that focuses on combination therapies for chronic conditions. Its unique formulation and delivery system make it an attractive option for patients and healthcare providers alike.

Competitive Landscape

The competitive landscape for hypertension treatments is robust, with several products vying for market share. However, COMBIPRES stands out due to its combination of two effective antihypertensive agents, making it a preferred choice for managing blood pressure in patients who require multiple medications[1].

Impact of Regulatory and Technological Trends

Regulatory and technological trends play a crucial role in the success of drug-device combination products like COMBIPRES.

Regulatory Support

Regulatory bodies are increasingly supportive of innovative combination products. This support encourages more investments in R&D, leading to the development of more effective and patient-centric treatments[1].

Technological Innovations

Technological innovations, such as smart drug delivery systems and digital health technologies, are enhancing the effectiveness and convenience of combination products. For example, the integration of wearable devices and mobile apps can improve patient compliance and treatment outcomes[1].

Patient-Centric Care and Cost-Effectiveness

The focus on patient-centric care and the need for cost-effective healthcare solutions are driving the adoption of drug-device combination products.

Improved Treatment Outcomes

Products like COMBIPRES offer improved treatment outcomes by combining multiple therapeutic agents into a single delivery system. This not only enhances patient compliance but also reduces the complexity of treatment regimens[1].

Reduced Hospital Stays

The use of combination products can lead to reduced hospital stays and lower healthcare costs. By managing chronic conditions more effectively, these products contribute to better overall health outcomes and reduced healthcare expenditure[1].

Future Outlook

The future outlook for drug-device combination products, including COMBIPRES, is promising.

Continued Innovation

The market is expected to see continued innovation, with new products and technologies being developed. This includes the integration of AI and machine learning into drug delivery systems, further enhancing patient care[1].

Expanding Market Access

As healthcare access improves globally, the market for combination products is expected to expand. Emerging markets, particularly in Asia and Latin America, will play a significant role in the future growth of this sector[4].

Key Takeaways

• The global market for drug-device combination products is projected to reach $158.7 billion by 2030.
• Technological advancements, favorable regulatory environments, and the rising prevalence of chronic diseases are key drivers.
• Regional markets, such as the U.S. and China, are showing significant growth.
• Products like COMBIPRES benefit from being part of a growing market segment focused on combination therapies for chronic conditions.
• Regulatory support and technological innovations are crucial for the success of these products.
• The focus on patient-centric care and cost-effectiveness is driving the adoption of these products.

FAQs

What are the key drivers of the drug-device combination products market?

The key drivers include technological advancements, favorable regulatory environments, and the rising prevalence of chronic diseases.

How is the regional market for drug-device combination products performing?

The U.S. market was estimated at $30.6 billion in 2023, while China is forecasted to grow at an 8.3% CAGR to reach $36.2 billion by 2030.

What is the financial trajectory of companies involved in drug-device combination products?

Companies are experiencing robust financial performance, with projected revenues reaching $158.7 billion by 2030 and strong growth from newly launched products.

How does COMBIPRES benefit from market trends?

COMBIPRES benefits from being part of a growing market segment focused on combination therapies for chronic conditions, with its unique formulation and delivery system making it an attractive option.

What role do technological innovations play in the success of drug-device combination products?

Technological innovations, such as smart drug delivery systems and digital health technologies, enhance the effectiveness and convenience of these products, improving patient compliance and treatment outcomes.

Sources

1. ResearchAndMarkets.com: "Drug Device Combination Products - Global Strategic Business Report" - October 31, 2024.
2. PR Newswire: "UCB on Growth Path for a Decade Plus" - February 28, 2024.
3. Pfizer: "Fourth-Quarter 2022 Earnings Conference Call Prepared Remarks" - January 31, 2023.
4. IQVIA: "IQVIA Quarterly Pharmaceutical Market Outlook" - November 2023.